KRAS mutations were also shown to be functionally involved in the downregulation of major histocompatibility complex (MHC) class I molecules, thereby causing the reduced ability of CD8+ cytotoxic T cells to recognise cancer cells69. The gene discussed is CD8A; the disease is cancer.